Previous Section
Clinical Trials
31. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial.
- Author
- von Minckwitz G; Kummel S; Vogel P; Hanusch C; Eidtmann H; Hilfrich J; Gerber B; Huober J; Costa SD; Jackisch C; Loibl S; Mehta K; Kaufmann M;
- Institution
- German Breast Group, Frankfurt, Germany. minckwitz@germanbreastgroup.de
- Journal
- J Natl Cancer Inst. 2008 Apr 16;100(8):542-51. Epub 2008 Apr 8.
- Abstract URL
- Click here to view abstract
32. Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study.
- Author
- von Minckwitz G; Kummel S; Vogel P; Hanusch C; Eidtmann H; Hilfrich J; Gerber B; Huober J; Costa SD; Jackisch C; Loibl S; Mehta K; Kaufmann M;
- Institution
- German Breast Group, Frankfurt, Germany. minckwitz@germanbreastgroup.de
- Journal
- J Natl Cancer Inst. 2008 Apr 16;100(8):552-62. Epub 2008 Apr 8.
- Abstract URL
- Click here to view abstract
33. Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial.
- Author
- Greenspan SL; Brufsky A; Lembersky BC; Bhattacharya R; Vujevich KT; Perera S; Sereika SM; Vogel VG;
- Institution
- Department of Medicine, University of Pittsburgh, 3471 Fifth Ave, Kaufmann Suite 1110, Pittsburgh, PA 15213, USA. greenspans@dom.pitt.edu
- Journal
- J Clin Oncol. 2008 Jun 1;26(16):2644-52. Epub 2008 Apr 21.
- Abstract URL
- Click here to view abstract
34. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
- Author
- Thomas ES;
- Institution
- Journal
- J Clin Oncol. 2008 May 1;26(13):2223.
35. Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study.
- Author
- Awada A; Albanell J; Canney PA; Dirix LY; Gil T; Cardoso F; Gascon P; Piccart MJ; Baselga J;
- Institution
- Medical Oncology Clinic, Institut Jules Bordet, Brussels, Belgium. ahmad.awada@bordet.be
- Journal
- Br J Cancer. 2008 May 6;98(9):1500-7. Epub 2008 Apr 29.
- Abstract URL
- Click here to view abstract
36. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
- Author
- Martin M; Rodriguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munarriz B; Rodriguez CA; Crespo C; de Alava E; Lopez Garcia-Asenjo JA; Guitian MD; Almenar S; Gonzalez-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Segui MA; Mayordomo JI; Anton A; Baena JM; Plazaola A; Modolell A; Pelegri A; Mel JR; Aranda E; Adrover E; Alvarez JV; Garcia Puche JL; Sanchez-Rovira P; Gonzalez S; Lopez-Vega JM;
- Institution
- Servicio de Oncologia Medica, Hospital Universitario San Carlos, Ciudad Universitaria s/n, 28040 Madrid, Spain. mmartin@geicam.org
- Journal
- J Natl Cancer Inst. 2008 Jun 4;100(11):805-14. Epub 2008 May 27.
- Abstract URL
- Click here to view abstract
37. Neoadjuvant paclitaxel for operable breast cancer: multicenter phase II trial with clinical outcomes.
- Author
- Kimura M; Sano M; Fujimori M; Nakagomi H; Negishi T; Yanagita Y; Sato N;
- Institution
- Department of Surgery, General Ota Hospital, Ota, Gunma 373-8585, Japan. kimuraota@yahoo.co.jp
- Journal
- Anticancer Res. 2008 Mar-Apr;28(2B):1239-44.
- Abstract URL
- Click here to view abstract
38. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer.
- Author
- Gomez HL; Doval DC; Chavez MA; Ang PC; Aziz Z; Nag S; Ng C; Franco SX; Chow LW; Arbushites MC; Casey MA; Berger MS; Stein SH; Sledge GW;
- Institution
- Instituto Nacional de Enfermedades Neoplasicas, Hospital Alberto Sabogal, Lima, Peru. hgomez@inen.sld.pe
- Journal
- J Clin Oncol. 2008 Jun 20;26(18):2999-3005. Epub 2008 May 5.
- Abstract URL
- Click here to view abstract
39. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.
- Author
- Seidman AD; Berry D; Cirrincione C; Harris L; Muss H; Marcom PK; Gipson G; Burstein H; Lake D; Shapiro CL; Ungaro P; Norton L; Winer E; Hudis C;
- Institution
- Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA. seidmana@mskcc.org
- Journal
- J Clin Oncol. 2008 Apr 1;26(10):1642-9.
- Abstract URL
- Click here to view abstract
40. Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer.
- Author
- Rivera E; Mejia JA; Arun BK; Adinin RB; Walters RS; Brewster A; Broglio KR; Yin G; Esmaeli B; Hortobagyi GN; Valero V;
- Institution
- Department of Breast Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
- Journal
- Cancer. 2008 Apr 1;112(7):1455-61.
- Abstract URL
- Click here to view abstract
Next: Radiation Therapy
